Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-755 | Immune Thrombotic Thrombocytopenic Purpura (iTTP) | Phase 2b | Ongoing | Intravenous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-906 | Gastroparesis | Phase 2b | Ongoing | oral | Gastroenterology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-861 | Narcolepsy Type 2 | Phase 2b | Trial Discontinued | Oral | Neurology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | ZED1227/TAK-227 | Celiac disease | Phase 2b | Ongoing | Oral | Gastroenterology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-994 | Narcolepsy | Phase 2 | Trial Discontinued | Oral | Neurology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-041 / NBI-1065846 | Anhedonia in depression | Phase 2 | Data Released | Oral | Psychiatric |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-653 / NBI-1065845 | Major Depressive Disorder (MDD) | Phase 2 | Data Released | Oral | Psychiatric |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | TAK-831 / Luvadaxistat (NBI-1065844) | Negative symptoms of schizophrenia | Phase 2 | Trial Discontinued | Oral | Psychiatric |
